BR0312204A - Antagonista de receptor ccr5 de quinolina substituìda - Google Patents

Antagonista de receptor ccr5 de quinolina substituìda

Info

Publication number
BR0312204A
BR0312204A BR0312204-2A BR0312204A BR0312204A BR 0312204 A BR0312204 A BR 0312204A BR 0312204 A BR0312204 A BR 0312204A BR 0312204 A BR0312204 A BR 0312204A
Authority
BR
Brazil
Prior art keywords
ccr5 receptor
receptor antagonist
substituted quinoline
quinoline
receptor antagonists
Prior art date
Application number
BR0312204-2A
Other languages
English (en)
Inventor
Laura Dunning
Stefan Jaroch
Monica J Kochanny
Wheeseong Lee
Xiongdong Lian
Meina Liang
Shou-Fu Lu
James Onuffer
Gary Phillips
Guo-Ping Wei
Bin Ye
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0312204A publication Critical patent/BR0312204A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"ANTAGONISTAS DE RECEPTOR CCR5 DE QUINOLINA SUBSTITUìDA". A presente invenção refere-se ao antagonistas de receptor CCR5 das fórmulas (1a) ou (1b): enantiómeros, diastereómeros, sais e solvatos dos mesmos, onde R^ 1^, R^ 2^, R^ 3^, R^ 4^, R^ 5^, E R^ 7^ são conforme definidos aqui. A invenção inclui, adicionalmente, um processo de distúrbios mediados por CCRS empregando tais compostos.
BR0312204-2A 2002-06-27 2003-06-24 Antagonista de receptor ccr5 de quinolina substituìda BR0312204A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45168702P 2002-06-27 2002-06-27
PCT/US2003/020950 WO2004002960A1 (en) 2002-06-27 2003-06-24 Substituted quinoline ccr5 receptor antagonists

Publications (1)

Publication Number Publication Date
BR0312204A true BR0312204A (pt) 2005-04-26

Family

ID=30001033

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312204-2A BR0312204A (pt) 2002-06-27 2003-06-24 Antagonista de receptor ccr5 de quinolina substituìda

Country Status (17)

Country Link
US (1) US7220856B2 (pt)
EP (1) EP1534681A1 (pt)
JP (1) JP2005537247A (pt)
CN (1) CN1678586A (pt)
AR (1) AR040349A1 (pt)
AU (1) AU2003247772A1 (pt)
BR (1) BR0312204A (pt)
CA (1) CA2489560A1 (pt)
IL (1) IL165871A0 (pt)
MX (1) MXPA05000081A (pt)
NO (1) NO20050429L (pt)
PE (1) PE20040687A1 (pt)
RU (1) RU2005102004A (pt)
TW (1) TW200401774A (pt)
UY (1) UY27871A1 (pt)
WO (1) WO2004002960A1 (pt)
ZA (1) ZA200500790B (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
TWI283665B (en) * 2001-09-13 2007-07-11 Smithkline Beecham Plc Novel urea compound, pharmaceutical composition containing the same and its use
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
JP2006519806A (ja) * 2003-03-07 2006-08-31 グラクソ　グループ　リミテッド 尿素誘導体および疼痛治療におけるバニロイド受容体拮抗剤としてのそれらの使用。
CA2518398A1 (en) * 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
CN1835756A (zh) * 2003-08-15 2006-09-20 默克公司 有丝分裂驱动蛋白抑制剂
AU2011265309B2 (en) * 2003-11-21 2014-06-05 Array Biopharma, Inc. AKT protein kinase inhibitors
KR101223914B1 (ko) 2003-11-21 2013-01-18 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제
US20080119471A1 (en) * 2004-02-24 2008-05-22 Ulrike Kaufmann Piperazine urea derivatives for the treatment of endometriosis
NZ550370A (en) 2004-04-13 2009-09-25 Incyte Corp Piperazinylpiperidine derivatives as chemokine receptor antagonists
JP2008506695A (ja) * 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
EP1864971A4 (en) * 2005-03-31 2010-02-10 Takeda Pharmaceutical PROPHYLACTIC / THERAPEUTIC AGENT AGAINST DIABETES
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US20070004763A1 (en) * 2005-06-10 2007-01-04 Nand Baindur Aminoquinoline and aminoquinazoline kinase modulators
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
CN106474118A (zh) 2005-09-19 2017-03-08 诺伊罗纳森特公司 刺激神经形成和抑制神经元变性的方法和组合物
AU2013211455B2 (en) * 2005-09-19 2017-12-07 Neuronascent, Inc. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
BRPI0811745B1 (pt) * 2007-05-17 2019-06-04 Helperby Therapeutics Limited Compostos de 4-(pirrolidin-1-il)quinolina, uso e processo para a preparação dos mesmos, formulação farmacêutica --
WO2011078369A1 (ja) * 2009-12-25 2011-06-30 持田製薬株式会社 新規アリールウレア誘導体
CN103596927A (zh) * 2011-06-06 2014-02-19 希格马托制药工业公司 用于合成7-氯-4-(哌嗪-1-基)-喹啉的新方法
AU2012273125B2 (en) 2011-06-19 2017-05-25 New York University Leukotoxin E/D as a new anti-inflammatory agent and microbicide
EP2822936B1 (en) * 2012-03-07 2021-09-08 The McLean Hospital Corporation Aminoquinoline derivatives and uses thereof
CA2877526A1 (en) 2012-06-20 2013-12-27 Novartis Ag Complement pathway modulators and uses thereof
SG11201503959VA (en) * 2012-11-20 2015-06-29 Merial Inc Anthelmintic compounds and compositions and method of using thereof
WO2014134705A1 (en) * 2013-03-04 2014-09-12 Advanced Medical Research Institute Of Canada Quinoline sulfonyl derivatives and uses thereof
WO2016161960A1 (en) 2015-04-10 2016-10-13 Beigene, Ltd. NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
CA3012832A1 (en) 2016-02-05 2017-08-10 Denali Therapeutics Inc. N-azepinyl-carboxamide inhibitors of receptor-interacting protein kinase1
EP3452450A1 (en) * 2016-05-04 2019-03-13 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
SI3452465T1 (sl) * 2016-05-04 2021-04-30 Genoscience Pharma Substituirani derivati 2,4-diamino-kinolina za uporabo v zdravljenju proliferativnih bolezni
WO2018034917A1 (en) * 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
US10414774B2 (en) * 2016-08-15 2019-09-17 Merck Sharp & Dohme Corp. Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease
EP3503916A1 (en) 2016-08-26 2019-07-03 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10882856B2 (en) 2016-09-24 2021-01-05 Beigene, Ltd. 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases
RS63203B1 (sr) 2016-12-09 2022-06-30 Denali Therapeutics Inc Jedinjenja korisna kao inhibitori ripk1
SG11202000248UA (en) * 2017-07-14 2020-02-27 Innate Tumor Immunity Inc Nlrp3 modulators
EP3676252B1 (en) * 2017-08-29 2023-11-29 Chulabhorn Foundation Derivatives and composition of quinoline and naphthyridine
CN111386114A (zh) * 2017-11-25 2020-07-07 百济神州有限公司 作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑
WO2019129114A1 (zh) * 2017-12-29 2019-07-04 杭州阿诺生物医药科技有限公司 吲哚胺2,3-双加氧酶抑制剂以及它们在医学上的应用
CN111471035B (zh) * 2017-12-29 2021-02-26 杭州阿诺生物医药科技有限公司 一类ido抑制剂的制备方法
JP7373512B2 (ja) 2018-06-27 2023-11-02 ブリストル－マイヤーズ スクイブ カンパニー Ｔ細胞アクティベーターとして有用なナフチリジノン化合物
SG11202012972YA (en) 2018-06-27 2021-01-28 Bristol Myers Squibb Co Substituted naphthyridinone compounds useful as t cell activators
EP3620164A1 (en) * 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
CN113891880A (zh) * 2019-05-22 2022-01-04 百济神州有限公司 作为吲哚胺2,3-双加氧酶的选择性抑制剂的酰胺取代的咪唑并化合物
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
WO2021105497A1 (en) * 2019-11-29 2021-06-03 University Of Copenhagen Small-molecule nadph oxidase 2 inhibitors
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
CN112979546B (zh) * 2021-02-25 2023-01-31 中国药科大学 一类丁酰胆碱酯酶选择性抑制剂及其制备方法与用途
WO2022204720A1 (en) * 2021-03-26 2022-09-29 Sumitomo Pharma Oncology, Inc. (furopyrimidin-4-yl)piperazine compounds and uses thereof
WO2023137035A1 (en) 2022-01-12 2023-07-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
WO2024017858A1 (en) 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel naphthyl and isoquinoline sulfonamide derivatives
WO2024049718A2 (en) * 2022-08-31 2024-03-07 Immunocure Inc. Quinoline piperazine derivatives, pharmaceutical composition and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR84902E (fr) * 1962-08-30 1965-05-07 Rhone Poulenc Sa Nouveaux dérivés de la quinoléine et leur préparation
US5494908A (en) * 1992-11-23 1996-02-27 Hoechst-Roussel Pharmaceutical Incorporated Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
JP4073961B2 (ja) * 1996-10-01 2008-04-09 協和醗酵工業株式会社 含窒素複素環化合物
WO1998027815A1 (en) 1996-12-20 1998-07-02 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
JP2002508366A (ja) 1997-12-12 2002-03-19 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー キノリンピペラジンおよびキノリンピペリジン誘導体、それらの製造方法、ならびに複合的５−ｈｔ１ａ、５−ｈｔ１ｂおよび５−ｈｔ１ｄ受容体アンタゴニストとしてのそれらの用途
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
US6344450B1 (en) * 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
CN1091103C (zh) * 1999-04-02 2002-09-18 中国科学院上海药物研究所 一类喹诺酮类化合物及它的制备和其用途
JP4101053B2 (ja) 2000-08-10 2008-06-11 田辺三菱製薬株式会社 プロリン誘導体及びその医薬用途
CA2419219A1 (en) * 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
US6960580B2 (en) 2001-03-08 2005-11-01 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic substituted quinoline compounds
MY140679A (en) * 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same

Also Published As

Publication number Publication date
TW200401774A (en) 2004-02-01
AU2003247772A1 (en) 2004-01-19
US20040072818A1 (en) 2004-04-15
MXPA05000081A (es) 2005-04-11
CN1678586A (zh) 2005-10-05
NO20050429D0 (no) 2005-01-26
AR040349A1 (es) 2005-03-30
RU2005102004A (ru) 2005-10-20
EP1534681A1 (en) 2005-06-01
JP2005537247A (ja) 2005-12-08
CA2489560A1 (en) 2004-01-08
IL165871A0 (en) 2006-01-15
WO2004002960A1 (en) 2004-01-08
PE20040687A1 (es) 2004-12-01
ZA200500790B (en) 2006-10-25
NO20050429L (no) 2005-03-29
UY27871A1 (es) 2003-12-31
US7220856B2 (en) 2007-05-22

Similar Documents

Publication Publication Date Title
BR0312204A (pt) Antagonista de receptor ccr5 de quinolina substituìda
ATE382353T1 (de) Substiuierte piperidine als melanocortinrezeptor- modulatoren
DE60222396D1 (de) N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
DK1263752T3 (da) LPA-receptoragonister og -antagonister og fremgangsmåde til anvendelse heraf
NO20022857L (no) Nye P2X7-reseptoragonister for bruk i behandling av inflammatoriske, immun- eller kardiovaskul¶re sykdommer
TR200101155T2 (tr) 4-Aroil Piperidin CCR-3 Reseptör Antagonistleri III
EA200100588A1 (ru) Пиперидины как модуляторы ccr5
ES2072096T3 (es) 4-fenilpiperidinas n-sustituidas antagonistas de opioides.
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
ATE328879T1 (de) Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv
ATE413388T1 (de) Muskarin antagonisten
ATE399770T1 (de) Tachykininrezeptorantagonisten
NO20061981L (no) Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
NO985518D0 (no) Morfinanderivater og medisinsk anvendelse derav
EA200400467A1 (ru) Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора
DE60206198T2 (de) Tetrahydrochinolinderivate als muscarinische agonisten
DE60213629D1 (de) Piperidinverbindungen als muscarinantagonisten
DE60312474D1 (de) 5-ht3-rezeptorantagonisten und verwendungsverfahren
ATE245156T1 (de) Aryl-annellierte disubstituierte pyridine : nk3 rezeptor-liganden
EA200500803A1 (ru) Антагонисты ccr1 для лечения воспалительных артритов, демиелинизационных воспалительных заболеваний
DE602004031410D1 (de) Inden derivate als pharmazeutika
BR0011122A (pt) Antagonistas de receptor il-8
BRPI0411867A (pt) tiofenilaminoimidazolinas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A. E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2064 DE 27/07/2010.